Story

Trump's CDC Nominee Erica Schwartz Faces Senate Confirmation Hearing Amid Agency Turmoil

ENTHMSVIIDZHZH-TWJAKOHI
Jul 15, 20262 min read
Trump's CDC Nominee Erica Schwartz Faces Senate Confirmation Hearing Amid Agency Turmoil

Summary

Erica Schwartz, President Trump's pick to lead the Centers for Disease Control and Prevention, will appear before a Senate panel for her confirmation hearing. The nomination comes as the CDC contends with leadership instability and major public health crises, including a measles resurgence and an Ebola outbreak.

Text size
Background

Erica Schwartz, President Donald Trump’s nominee to lead the U.S. Centers for Disease Control and Prevention (CDC), is appearing before a Senate committee on Wednesday for a confirmation hearing that could bring stable leadership to the agency after months of turmoil. The hearing is a critical step for the CDC, which has lacked a confirmed director for nearly all of Trump's second term, according to a Reuters report.

The Confirmation Process

Schwartz, who previously served as deputy surgeon general in Trump's first term, will face questions from the Senate Committee on Health, Education, Labor and Pensions. The hearing, led by Republican Senator and physician Bill Cassidy, is the first for a permanent CDC director since Susan Monarez was confirmed and subsequently fired last year.

Senator Cassidy called Schwartz "very impressive" following a meeting last month, signaling potential support. The committee will also hold a hearing for Sean Kaufman, Trump’s nominee for assistant secretary for preparedness and response, whose past comments questioning vaccines have drawn scrutiny.

A History of Leadership Instability

The CDC has faced significant leadership challenges. The agency's last confirmed director, Susan Monarez, was dismissed less than a month into her tenure after reported clashes with Health Secretary Robert F. Kennedy Jr. on vaccine policy.

Sample IUX Markets – In-articleAd

Prior to that, in March 2025, the administration withdrew its first nominee for the role, former Congressman Dave Weldon, just hours before his scheduled hearing after it became clear he lacked sufficient votes for confirmation. In contrast, Schwartz, a board-certified preventive medicine physician with no public record of opposing vaccines, is viewed as a more conventional nominee.

Pressing Public Health Crises

If confirmed, Schwartz will inherit an agency confronting several major public health emergencies. Key challenges include:

  • A resurgence of measles, with U.S. cases in the current year on track to surpass 2025's total, which was the highest since the disease was declared eliminated in 2000.
  • An international Ebola outbreak in the Democratic Republic of Congo and Uganda, which has prompted the CDC to activate its highest level of emergency response.
  • Eroding public confidence in vaccines, which officials cite as a driver of falling childhood immunization rates.

Read next

More on Stocks
Shenzhen-Listed Jingxin Pharmaceutical Refiles for Hong Kong IPO

Stocks

Shenzhen-Listed Jingxin Pharmaceutical Refiles for Hong Kong IPO

Sep 20, 2026

Zhejiang Jingxin Pharmaceutical Co., Ltd. (002020.SZ) has resubmitted its application for a main board listing on the Hong Kong Stock Exchange, aiming to secure a dual listing to access international capital. The company specializes in drugs for central nervous system and cardiovascular diseases.

Back to latest news

LATEST